All Clinical Trials
- All Clinical Trials
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-82.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018;48:35-43.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359-6.5
PEARL-III: This double-blind, placebo-controlled trial of 419 treatment-naïve patients with chronic hepatitis C infection genotype 1b examined the efficacy of 12 weeks of ombitasvir-paritaprevir-ritonavir and dasabuvir), with or without ribavirin. The SVR12 rate was 99.5% in the ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavirin group and 99.0% in patients who received ombitasvir-paritaprevir-ritonavir and dasabuvir without ribavirin. There was no statistically significant difference between these outcomes, and both demonstrated superiority to historical controls treated with telaprevir, peginterferon, and ribavirin. There were no relapses in either group. There were a greater number of adverse events reported in the ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavirin group when compared to the group that received ombitasvir-paritaprevir-ritonavir and dasabuvir without ribavirin (80% versus 67%, p=0.003), but there was no statistically significant difference in the number of serious or severe adverse events. PEARL-III was published in conjunction with the PEARL-IV trial.
PEARL-IV: This double-blind, placebo-controlled trial examined the efficacy of 12 weeks of ombitasvir-paritaprevir-ritonavir and dasabuvir with or without ribavirin in 305 treatment-naïve patients with chronic hepatitis C infection genotype 1a. In the group that received ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavirin, the SVR12 was 97.0%, compared with an SVR rate of 90.2% in the group that did not receive ribavirin. Both treatment arms demonstrated superiority to historical controls treated with a combination of telaprevir, peginterferon, and ribavirin. Among those patients who received ombitasvir-paritaprevir-ritonavir and dasabuvir without ribavirin, 2.9% showed virologic failure during treatment, and 5.2% demonstrated relapse. For the patients who received ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavirin, 1% showed virologic failure during treatment and 1% in this group demonstrated virologic relapse. There were a higher number of adverse events overall in the ribavirin arm compared with the placebo arm, but there was no statistically significant difference in the number of serious or severe adverse events. PEARL-IV was published in conjunction with the PEARL-III trial.![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 2016;150:1590-8.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Zeuzem S, Jacobson IM, Baykai T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-14.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-31.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-82.
![Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir Viekira Pak](http://cdn.hepatitisc.uw.edu/css/images/drugs/14.png)
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir
Tradename:Viekira PakOther Names:3DClass:Discontinued- Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64:301-307.